TACSTD2 and triple-negative breast carcinoma: However, a recent biomarker analysis from the ASCENT trial showed that sacituzumab govitecan achieved twice the ORR and progression-free survival duration in triple-negative breast cancer patients with TROP2-high or -medium as in those with TROP2-low [43].